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Chemical compounds built on a diazepine scaffold have recently emerged as potent inhibitors of the acetyl-
lysine binding activity of bromodomain-containing proteins, which is required for gene transcriptional activa-
tion in cancer and inflammation. Not only have these chemical compounds validated bromodomains as
attractive epigenetic drug targets, but they have also brought to the forefront another application of the dia-
zepine, which had already been regarded as a versatile chemical scaffold in rational drug design. This article
reviews the success of diazepine compounds as therapeutic agents and examines the unique chemical and
geometric features of this privileged scaffold that make it an excellent template for developing potent and
selective molecules that control bromodomain-related gene expression in human diseases.Natural products extracted from plants, animals, and microbes
have long been used as powerful chemical agents to treat
various human diseases. Whereas these compounds offer vast
structural diversity and high potency, their methods of action
against their target proteins are not always clearly elucidated,
largely due to the fact that they are difficult to synthesize or
isolate in large quantities—a challenging issue in the drug devel-
opment process (Carlson, 2010). As such, many research labo-
ratories and pharmaceutical companies have shifted their efforts
toward synthetic molecules that are chemically engineered to
interact in a specific manner with a known target protein.
As a synthetic chemistry-based drug discovery strategy
matured, researchers began to notice patterns in the physio-
chemical qualities that make certain chemical compounds
more ‘‘drug-like’’ and orally bioavailable than others (Lipinski,
2004). These considerations that allow for increased solubility
and absorption are succinctly described as Lipinski’s ‘‘rule of
five,’’ which states that a compound likely to possess a desired
absorption/permeability profile ought have fewer than five
hydrogen-bond donors, fewer than ten hydrogen-bond accep-
tors, a molecular weight less than 500 g per mole, and a calcu-
lated LogP (cLogP) less than 5 (Lipinski et al., 2001).
Structural patterns also emerged as certain chemical scaf-
folds were found to appear more frequently than others among
therapeutics that had succeeded in the clinic. These are referred
to as ‘‘privileged structures,’’ a term first used to describe the
benzodiazepine (BZD) scaffold when a compound composed
of this core was being developed as a nonpeptidal antagonist
of cholecystokinin (CKK) (Evans et al., 1986, 1988). BZDs con-
sist of a benzene ring fused to a diazepine—a seven-membered
heterocycle containing two nitrogen atoms, typically at positions
1 and 4 on the ring (Figure 1A). From a clinical perspective, the
BZD is regarded as a proven privileged scaffold because it
appears in many drugs that have been used for decades for anti-
convulsant, sedative, and anxiolytic purposes (Bermak et al.,
2007; Dubnick et al., 1983; Olkkola and Ahonen, 2008; Wang
et al., 1999). Among the most widely known and prescribed
members of the BZD family are diazepam, alprazolam, loraze-Chemistry & Bpam, and chlordiazepoxide (Figure 1B; Atack, 2005; Olkkola
and Ahonen, 2008; Verster and Volkerts, 2004; VonVoigtlander
and Straw, 1985).
It is doubtful that a privileged structure appears in many clini-
cally used drugs by chance—the structure likely has some
intrinsic value that enables its success on a wide array of thera-
peutic targets. A privileged structure, as defined in the literature,
should consist of ‘‘a single molecular framework able to provide
ligands for diverse receptors’’ (Evans et al., 1988). Such a chem-
ical structure provides a versatile template on which multiple
functional groups can be placed or chiral centers can be gener-
ated, allowingmedicinal chemists to utilize structure-based drug
design techniques to tailor a compound directly to its target
(Costantino and Barlocco, 2006; Horton et al., 2003; Huang
and Do¨mling, 2010; Patchett and Nargund, 2000). The ability of
the diazepine scaffold to present functional groups to many
different receptors can be seen in the enzyme inhibitors (Ander-
son et al., 2009; McGowan et al., 2009; Nyanguile et al., 2008;
Reid and Beese, 2004; Vandyck et al., 2009), G protein-coupled
receptor agonists (Joseph et al., 2008), and various other com-
pounds with diazepine-based scaffolds that have been devel-
oped (Figure 1C).
In recent years, BZDs and related compounds with a scaffold
of a diazepine fused to an isostere of benzene, thiophene
(Burger, 1991; Huang and Do¨mling, 2010; Huang et al., 2010),
have garnered considerable attention in drug discovery due to
multiple published studies detailing their interactions with the
bromodomains of the BET (bromodomain and extraterminal
domain) family proteins (Figure 1D). In this review article, we
describe the structural importance of the diazepine ring to a
variety of compounds that are built upon this core, as well as
how modifications of this central ring and its chemical substitu-
ents enable the development of potent and selective chemical
inhibitors of bromodomains. Such small molecule inhibitors
can not only help dissect the functions of bromodomain-contain-
ing proteins and provide mechanistic insights into their role in
gene transcription, but also continue to explore and validate bro-
modomains as potential epigenetic drug targets.iology 21, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 573
Figure 1. Key Structural and Chemical Features of Diazepine-Based Inhibitors
Names and structures of selected diazepine compounds are shown. If applicable, an alternate name (such as a trade name) is listed in parentheses.
(A) Pictured is the chemical structure of diazepam, a commonly prescribed benzodiazepine (BZD) drug, with the core BZD scaffold (blue) highlighted. Also
highlighted are two common variable regions (pink and yellow) especially important in the development of potent and selective bromodomain inhibitors. The pink
region is occupied by a triazole and the green region presents a pendant functional chain in the bromodomain inhibitors.
(B) Other diazepine compounds that target the GABAA receptor.
(C) Diazepine compounds that target various protein-protein interactions or enzymes. Compound 1 targets the HDM2/p53 interaction; BMS-214662 targets
farnesyltransferase; devazepide acts as a cholecystokinin antagonist.
(D) Diazepine compounds that target the BET bromodomains, alongwith the similar isoxazole azepine compound. (Citations for the structures in this figure can be
found in the text.)
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The therapeutic potential of the benzodiazepine scaffold was
first recognized in the late 1950s when scientists at Roche sub-
mitted a previously untested compound for pharmacological
evaluation. The compound was a remnant of previous research
that had been conducted by the company on quinazoline
N-oxides, and the scientists who submitted the compound
were not anticipating favorable results. As fate would have it,
this compound displayed strong sedative and muscle relaxant
properties, and represented a potential improvement over the
tranquilizers and hypnotics of the era. After intense investigation
of this compound and similar products, Roche introduced the
initial compound, chlordiazepoxide, to the market in 1960 under
the brand name of Librium, and in 1963, released a similar yet
more potent compound, diazepam, under the brand name of
Valium (Sternbach, 1979).
The early success of these compounds brought about a wide-
spread investigation of other benzodiazepines, as laboratories at
Roche and elsewhere searched for compounds with similar neu-
romodulatory effects. In the following years, many analogs were
produced and entered the clinic to produce various sedative,
anxiolytic, or relaxant effects in patients. Even as serotonin-spe-
cific reuptake inhibitors have taken the place of BZDs in the
treatment of certain anxiety disorders, BZDs are still widely574 Chemistry & Biology 21, May 22, 2014 ª2014 Elsevier Ltd All righused, and are being actively studied in the search for selective,
symptom-specific therapeutics (Griebel and Holmes, 2013;
Nash and Nutt, 2007; Skolnick, 2012; Stahl, 2002).
BZDs serve as CNS modulators by binding an allosteric site,
aptly named the BZD site, of ionotropic GABAA receptors (Olk-
kola and Ahonen, 2008). GABAA receptors are heteropentamers
made up of various different combinations of five subunits, taken
from a pool of 19 known subunits. The BZD site arises at the
junction of an a subunit (a1, a2, a3, or a5) and a g subunit (usually
g2; Rudolph and Knoflach, 2011). The most common BZDs are
agonists because their binding promotes increased binding of
GABA molecules to the active site of the GABAA receptor (Fig-
ures 1A and 1B). The enhanced rate of GABA binding increases
the frequency of chloride channel opening, which hyperpolarizes
the neuronal membrane and decreases the likelihood of an
action potential. Whereas agonists remain the most common
BZDs, other members of the BZD class are inverse agonists
that inhibit GABA from binding to its receptor, antagonists that
mitigate effects of agonists and inverse agonists, and com-
pounds that bind to peripheral BZD receptors (Wang et al.,
1999). BZDs such as chlordiazepoxide and diazepam gained
traction in the psychiatric community due to their superior effi-
cacy and safety over barbiturates, especially as the mechanism
of action of barbiturates on the GABAA receptor made overdosets reserved
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Nutt, 1999; Atack, 2005). However, dependency, tolerance,
and the potential for abuse are potential issues with the current
BZDs that limit their long-term use (Rudolph and Knoflach,
2011).
Studies have shown that steric effects and the lipophilic
nature of both the ligand and the binding site contribute greatly
to BZD binding (Borea and Bonora, 1983; Villar et al., 1991; Wie-
land et al., 1992). The ligands seem to bind to regions that are
quite sensitive to small additions of functional groups on the
BZD scaffold, an observation that was made previously in the
study of diazepine ligands that served either as cholecysto-
kinin-A agonists or antagonists (Patchett and Nargund, 2000).
Certain substitutions can increase activity against specific re-
ceptor subtypes, such as an electron-withdrawing group at
position 7 of the BZD (Loew et al., 1984; Sternbach, 1979;
Wang et al., 1999; Figure 1A). A methyl group at position 1 of
the BZD and modifications at positions 20 and 40 of the ring
attached at position 5 of the BZD can affect potency as well
(Sternbach, 1979). Multiple compounds, including alprazolam,
have a triazole ring anchored at positions 1 and 2 of the diaze-
pine in lieu of the carbonyl at position 2, providing activity
against different receptor subtypes (Filippakopoulos et al.,
2012a; VonVoigtlander and Straw, 1985; Figure 1B). From the
perspective of the ligand as a whole, it was demonstrated in
the early 1980s that the closed 7-membered ring of a 1,4-benzo-
diazepine was essential to the ligand’s effect on the CNS,
because the ring-opened form did not elicit the same activity
(Fryer et al., 1982). This is not surprising, because the spatial
presentation of functional groups to the receptor by the BZD
scaffold would seem to be vital to activity.
The BZDs serve as important chemical tools in the site-
directedmutagenesis studies that elucidate the functions of indi-
vidual receptor subtypes. Many studies were launched from the
finding that a single histidine residue at position 101 in the a1
subunit was vital for agonist binding, whereas the corresponding
residue in the a6 subunit, arginine, drastically reduces ligand
binding capability. When arginine was introduced to position
101 in the a1 subunit, agonist binding was lost, and moderate
agonist binding was gained when histidine was introduced to
the corresponding site in a6 (Wieland et al., 1992). Researchers
used this information to develop genetically altered mice with
histidine-to-arginine point mutations, and through the use of
BZD inhibition in the altered mice and in wild-type mice, were
able to determine the activities controlled by each a subtype
(Crestani et al., 2001, 2002; Lo¨w et al., 2000; McKernan et al.,
2000; van Rijnsoever et al., 2004; Rudolph et al., 1999; Rudolph
and Knoflach, 2011). It is not only this conserved histidine that is
important to agonist binding—receptor isoforms rely on many
different residues to interact with different functional groups on
BZD ligands (Amin et al., 1997; Buhr et al., 1996, 1997; Kucken
et al., 2000; Pritchett and Seeburg, 1991; Richter et al., 2012;
Wieland and Lu¨ddens, 1994).
The SAR data collected on the BZD ligands and the growing
knowledge of the functions of individual receptor subtypes pro-
vide tremendous opportunities for further research and potential
drug development. The differences in receptor subtypes and the
manner in which ligands make contact with different residues in
the BZD binding site are growing topics of interest in the psychi-Chemistry & Batric field, as researchers seek to exploit these differences to
develop anxioselective drugs (Atack, 2005; Estes, 1995;
McKernan et al., 2000; Skolnick, 2012). This wide array of inter-
actions accounts for the ability of some drugs to serve as anxio-
lytics, whereas others are sleep inducing or muscle relaxing
(McKernan et al., 2000; Sternbach, 1979; Villar et al., 1991). How-
ever, overlapping effects among these compounds is a concern,
and can bring about unintended problems. The ability to develop
agents with a singular purpose (i.e., a compound that can serve
as a daytime anxiolytic without inducing a sedative effect) may
become an attainable goal as additional data on these interac-
tions are obtained (Rudolph and Knoflach, 2011). In all, the
GABAA receptor continues to be an intriguing target with high
impact therapeutic potential, and compounds with BZD scaf-
folds have the potential to be at the center of new findings,
both literally and figuratively.
Versatility of the Diazepine Compounds
The unique physiochemical and structural qualities of diazepine
compounds have led researchers to investigate their effects
against a wide spectrum of drug targets beyond the GABAA re-
ceptor. For example, diazepine-based enzyme inhibitors have
been reported for farnesyltransferases (FTases; Reid and Beese,
2004; Figure 2A), mitogen-activated protein kinase-activated
protein kinase 2 (MK2; Anderson et al., 2009; Figure 2B), hepati-
tis C NS5B RNA polymerase (McGowan et al., 2009; Nyanguile
et al., 2008; Vandyck et al., 2009; Figure 2C), and histone deace-
tylases (HDACs; Loudni et al., 2007). Whereas each of these
compounds contains the diazepine core, they are rather distinct
from one another, placing each in a different subfamily. The
FTase inhibitor is a 1,4-BZD, theMK2 inhibitor a 1,4-thienodiaze-
pine, the HCV NS5B inhibitor a 1,5-BZD, and the HDAC inhibitor
is a 1,4-benzodiazepine-2,5-dione. This series of enzyme inhib-
itors demonstrates the chemical diversity among diazepine scaf-
folds themselves, not just in the functional groups that the
scaffolds present to their respective binding sites.
Diazepine compounds can mimic protein secondary struc-
tures, further expanding the realm of biological targets they
can act upon. BZD beta-turnmimics have been used as agonists
of the melanocortin system of GPCRs (Haskell-Luevano et al.,
1999; Joseph et al., 2008) and ligands with affinity for the angio-
tensin II receptor (Rosenstro¨m et al., 2006). A 1,4-benzodiaze-
pine-2,5-dione was also synthesized as an a helix mimic and
used to inhibit the HDM2 interaction with the tumor suppressor
protein p53 (Figure 2D; Grasberger et al., 2005; Leonard et al.,
2006). These peptidomimetic features displayed by diazepine-
based compounds reflect an expansive functional versatility,
as compounds can be generated that retain their cell perme-
ability and possess favorable pharmacokinetic and pharmaco-
dynamic properties as compared to typical peptide-based
chemical leads. It is evident that this rigid, multifaceted scaffold
possesses functionality against a multitude of targets, not simply
isoforms of the GABAA receptor. One way in which this knowl-
edge can be applied practically is through the development of
focused libraries of diazepine-based compounds, which could
be used to screen for new inhibitors of enzymes and protein-pro-
tein interactions (Welsch et al., 2010). Lead inhibitors emerging
from such a library would have a basic template known to have
favorable drug-like qualities, and possess the potential to beiology 21, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 575
Figure 2. Diazepine Compounds and Their Interactions with a Wide Variety of Targets
(A) The farnesyl-transferase inhibitor BMS-214662, a 1,4-BZD, in complex with a farnesyl diphosphate donor, FPP (Protein Data Bank [PDB] ID: 1SA5). The ligand
coordinates a catalytic zinc ion and forms van der Waals interactions with surrounding protein residues, notably stacking interactions with Y361, W102, and
W106. Water molecules near the binding pocket are represented by red spheres.
(B) A 1,4-thienodiazepine, 18, in complex with MK2 (PDB ID: 3FYK). Selectivity for MK2 over CDK2 is conferred through interactions with the K93 and D207 side
chains, as well as the backbone atoms of L141 and E190.
(C) A 1,5-BZD, 11d, in complex with the HCV NS5B RNA Polymerase (PDB ID: 3GOL). The ligand binds to its target through a network of interactions with water
molecules (the bound water from the ‘‘A’’ monomer of the crystal structure is depicted as a red sphere) and nearby side chains.
(D) A 1,4-benzodiazepine-2,5-dione, 1, in complex with HDM2 (PDB ID: 1T4E). The ligand mimics an a helix of a p53 peptide that interacts with HDM2, displaying
the benzodiazepine’s versatility. In addition to interactions with the same hydrophobic side chains as the p53 peptide, this ligand gains affinity through in-
teractions with bound water molecules (red spheres) and the highlighted residues.
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to fit individual targets.
Diazepines as New Bromodomain Inhibitors
The most recently recognized protein targets for diazepine-
based compounds are a group of bromodomains, which are
evolutionarily conserved protein modules embedded in a large576 Chemistry & Biology 21, May 22, 2014 ª2014 Elsevier Ltd All righnumber of transcription and chromatin regulator proteins. First
reported as the acetyl-lysine binding domain in the transcrip-
tional co-activator PCAF in 1999 (Dhalluin et al., 1999), the bro-
modomain functions to bind acetylated lysines in histones and
nonhistone proteins, thereby controlling acetylation-mediated
protein-protein interactions in gene transcription in chromatin
(Figures 3A and 3B). The human genome contains 61 uniquets reserved
Figure 3. Bromodomain Inhibitors Modulate Acetylation-Mediated Gene Transcriptional Activation in Chromatin
(A) Under physiological cellular conditions, the enzymes that regulate lysine acetylation and methylation of histone tails facilitate the opening and closing of
chromatin, which in turn, activates or represses gene transcription, respectively. The epigenome reader domains that recognize these marks direct the formation
of multi-protein complexes containing either the transcriptional machinery or other proteins responsible for maintaining the repressive state. A bromodomain
inhibitor (BrDi) can inhibit gene transcriptional activation by blocking acetylation-mediated protein-protein interactions required for chromatin remodeling and
transcription machinery recruitment. This effect can also result in transcriptional repression through H3 lysine 27 methylation-mediated chromatin compaction.
(B) Lysine acetylation of transcription factors is functionally important to their recruitment to target gene sites and assembly into the activated transcriptional
machinery through interactions with bromodomain-containing chromatin regulatory proteins (CRPs) or histone modifying enzymes such as histone acetyl-
transferases (HATs). Green dots refer to lysine acetylation sites on transcription proteins.
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ppakopoulos et al., 2012b). Each bromodomain is approximately
110 amino acids long and has a conserved structural fold—a left-
handed four-helix bundle, with helices termed aZ, aA, aB, and aC.
Two interhelical loops (the ZA loop, connecting aZ and aA, and
the BC loop, between aB and aC) form a hydrophobic pocket in
which the acetylated lysine of an associated protein can bind
(Figure 4A; Dhalluin et al., 1999). The key interaction that facili-
tates this binding is a hydrogen bond formed between a
conserved asparagine residue and the carbonyl oxygen of the
acetyl group (Figure 4B; Owen et al., 2000). In addition to this
asparagine, a network of conserved water molecules and other
conserved residues in the ZA and BC loops give the bromodo-
mains the ability to bind acetylated lysine. Selectivity among
binding partners within the family arises from subtle sequence
variations in the two loops (Filippakopoulos et al., 2012b; Muj-
taba et al., 2007).
Due to their interactions with a number of diazepine-based in-
hibitors, the bromodomains of the BET proteins are arguably the
most well-characterized human bromodomains to date. All BET
family proteins (BRD2, BRD3, BRD4, and BRDT) utilize tandem
bromodomains (BrD1 and BrD2) to bind to acetylated histones,Chemistry & Band an extraterminal (ET) domain to interact with other chro-
matin-associated proteins (Florence and Faller, 2001). The BET
bromodomains can also interact with nonhistone proteins that
regulate transcription, DNA replication, cell cycle, and other
cellular functions (Wu and Chiang, 2007). The BET family pro-
teins, especially BRD4, have recently been shown to play an
important role in the pathways that cause multiple types of can-
cer, including acute myeloid leukemia (Zuber et al., 2011), mixed
lineage leukemia (Dawson et al., 2011), multiple myeloma (Mertz
et al., 2011), and an aggressive form of squamous carcinoma
called NUT (nuclear protein in testis) midline carcinoma (Filippa-
kopoulos et al., 2010; French et al., 2001, 2003, 2008; Reynoird
et al., 2010). These clinically relevant studies have validated the
BET bromodomains as attractive epigenetic cancer therapy tar-
gets and also displayed the need for potent and selective bromo-
domain inhibitors (Belkina and Denis, 2012; Furdas et al., 2012;
Muller et al., 2011).
The versatility of diazepine compounds makes them excellent
candidates to modulate bromodomain/acetyl-lysine binding
functions in gene transcription. The Mitsubishi Tanabe Pharma-
ceutical Corporation first reported thienotriazolodiazepines tar-
geting the bromodomains of the BET family proteins as inhibitorsiology 21, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 577
Figure 4. Molecular Basis of Ligand
Recognition by the BRD4-BrD1
(A) Crystal structure of BRD4-BrD1 in complex with
a di-acetylated histone H4 peptide, H4K12ac/
H4K16ac (PDB ID: 3UVX). The bound water mole-
cules are depicted as pink spheres.
(B) Crystal structure of BRD4-BrD1 bound to
H4K12ac/H4K16ac peptide superimposed with BrD
inhibitor MS417. The key conserved residue Asn140
responsible for recognizing the acetyl-lysine in the
binding pocket is highlighted. The five structured
water molecules at the base of the binding pocket
are shown as red spheres (ligand) and pink spheres
(peptide).
(C–F) Structural depictions of the BRD4-BrD1
bound to diazepine- or azepine-based BrD in-
hibitors, JQ1 (PDB ID: 3MXF), MS417 (PDB ID:
4F3I), I-BET (PDB ID: 3P5O), or isoxazole azepine 3
(PDB ID: 4LRG), respectively. Motifs unique to each
individual ligand at position C3 are highlighted in
yellow, and BRD4 residues important for ligand
recognition are noted. D144 in BRD4-BrD1 that is
not conserved in BRD4-BrD2, is highlighted in
orange. The bound water molecules at the base of
the binding pocket are indicated as red spheres.
Orange dashed lines feature the network of
hydrogen bonds in the acetyl-lysine binding pocket
among the triazole ring, key protein residues, and
water molecules.
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2006 and 2008 (Adachi et al., 2006; Miyoshi et al., 2008).
Increased knowledge of BET family bromodomains and their
emergence as attractive drug targets led multiple research
groups to build on the scaffold put forth by Mitsubishi Tanabe
and develop nanomolar-affinity inhibitors of their own. One
such effort yielded a thienotriazolodiazepine named JQ1, which
binds tightly to BRD4 bromodomains, but not to the GABAA re-
ceptor nor to other non-BET bromodomains (Filippakopoulos
et al., 2010). The BZD GSK525762A (referred to as I-BET; Nico-578 Chemistry & Biology 21, May 22, 2014 ª2014 Elsevier Ltd All rights reserveddeme et al., 2010) and another further
improved thienotriazolodiazepine, MS417
(Miyoshi et al., 2008; Zhang et al., 2012),
have also been published as potent inhibi-
tors of BET bromodomains. The core
structures of these ligands (Figure 1D) are
similar to those of the clinical BZDs (Fig-
ures 1A and 1B), but various unique substi-
tutions confer their specificity for the
bromodomains.
Structural Considerations of BET
Bromodomain Inhibition
The inhibitors of BET protein bromodo-
mains bind in the acetyl-lysine binding
pocket, serving as orthosteric modulators
of function (Figures 4A and 4B; Chung
et al., 2011), directly contrasting with the
allosteric mechanism utilized by BZDs
that bind to the GABAA receptor. Within
this pocket, the triazole ring found on
each of the highlighted BET-specific inhib-
itors mimics the acetyl group of the typicalbiological ligand. The two nitrogen atoms of the ring that enter
into the pocket interact with the network of bound water mole-
cules and the conserved asparagine and tyrosine residues
(Asn140 and Tyr97 in BRD4-BrD1). The methyl group attached
to the triazole ring binds in a deep region of the pocket that is
responsible for recognizing the methyl portion of the acetyl
group of an acetyl-lysine. The diazepine scaffold plays a major
role in directing how these inhibitors fit into the pocket. JQ1,
which has a thienodiazepine scaffold, is described as having
‘‘an extraordinary shape complementarity with the KAc binding
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et al., 2010). The BZD scaffold of I-BET is also described as hav-
ing a curvature to it that helps the ligand extend beyond the bind-
ing region that a lysine-acetylated histone would occupy, deep
into a lipophilic pocket called the ZA channel (Chung et al.,
2011; Nicodeme et al., 2010). These features illustrate that the
triazolodiazepine inhibitors not only have the ability to mimic
the important interactions that facilitate acetyl-lysine binding,
but also that they sterically complement the binding site.
As alluded to above, the functional groups presented by the
diazepine scaffold make important hydrophobic contacts just
outside of the acetyl-lysine binding pocket in the ZA and
BC loops. The WPF shelf, a tryptophan-proline-phenylalanine
sequence found in all BET bromodomains (Trp81, Pro82,
Phe83 in BRD4-BrD1), interacts with the pendant phenyl group
of the highlighted diazepine inhibitors (Chung et al., 2011; Nic-
odeme et al., 2010). Access to this region is controlled by the
so-called ‘‘gatekeeper’’ residue (Ile146 in BRD4-BrD1), which
has been found to adopt a different conformation in the apo
form of BRD4-BrD1 as opposed to the ligand-bound form of
the domain (Filippakopoulos et al., 2012a; Prinjha et al., 2012).
The gatekeeper residue is an isoleucine in the BrD1 of each
of the BET proteins, while it is a valine in the BrD2. However,
other bromodomains, such as those of PCAF and GCN5,
have a tyrosine as their gatekeeper residue. This explains the
high selectivity of this class of diazepine inhibitors for the BET
protein bromodomains. The presence of a bulkier gatekeeper
residue may prevent the pendant phenyl ring of these com-
pounds from interacting with the WPF shelf, disrupting binding
(Chung, 2012).
Analysis of the top BET-specific inhibitors shows that stereo-
chemistry plays an important role in their binding modes. Potent
inhibitors all have substituents in the S configuration at position
C3 of their diazepine rings (blue highlights in Figures 4C and
4E). R-enantiomers of JQ1, I-BET, and MS417 were tested
against BRD4-BrD1 and other BET family members, and all
proved inactive due to steric clashes with Leu92 and Leu94,
and in the case of MS417’s enantiomer, Tyr139 (Chung et al.,
2011; Filippakopoulos et al., 2010; Zhang et al., 2012).
Aside from its stereochemistry, the moiety attached to C3 is
important to take into account, especially when considering
potential off-target effects of BET inhibitors. Because their scaf-
folds are so similar to the CNS-targeted BZDs used in the clinic,
diazepine-based bromodomain inhibitors must be carefully con-
structed to not induce these neurological effects in the patients
who may be receiving them. For example, one of the main struc-
tural features of JQ1 is a bulky t-butyl ester group attached at C3
(Figure 4C), which is cited as the reason that JQ1 shows little
activity against the BZD allosteric binding site on the GABAA re-
ceptor (Filippakopoulos et al., 2010). Indeed, previous SAR
studies on BZDs show that bulky groups at C3 greatly reduce
the activity of a diazepine compound against its neurological
target (Borea and Bonora, 1983). Additionally, recently published
data indicate that BZDs targeted for the bromodomain do not
interact with the GABAA receptor if certain substituents are intro-
duced at either the meta or para positions of the pendant phenyl
ring (Mirguet et al., 2013). Depending on the ligand, it appears
that groups at both sites may have the potential to prevent off-
target interactions.Chemistry & BMS417 and I-BET, alternatively, seek to limit off-target effects
with moieties at C3 that increase affinity for BET protein bromo-
domains, rather than relying on the prevention of other interac-
tions. MS417 contains a methyl ester at this position (Figure 4D)
and I-BET contains an ethyl amine (Figure 4E), as opposed to the
bulky t-butyl ester of JQ1 (Zhang et al., 2012). The crystal struc-
ture of the BRD4-BrD1/MS417 complex shows that the ligand
not only binds deep in the acetyl-lysine binding pocket like its
counterparts do, but also its methyl ester group makes contacts
with Leu94 and Tyr139 in a hydrophobic cavity between the ZA
and BC loops. Whereas the t-butyl group of JQ1 is too large to
fit into this cavity, MS417 utilizes these contacts to boost affinity
for both BRD4-BrD1 and BRD4-BrD2 by 5- to 10-fold as
compared to those of JQ1. Additionally, the BZD SAR data cited
above (Borea and Bonora, 1983) shows that themethyl ester and
ethyl amine may still be large enough functional groups to pre-
vent interactions with the BZD binding site on the GABAA recep-
tor. Therefore, MS417 and I-BET have both improved BET family
affinity and a potentially similar block against off-target effects
as JQ1.
The differences among diazepines designed to inhibit BET
protein bromodomains and those that bind to the GABAA recep-
tor have been further elucidated through the testing of the
GABAA agonists against the BET bromodomains (Filippakopou-
los et al., 2012a). The data from this paper show that alprazolam
and midazolam interact with the BET bromodomains, but due to
altered interactions with conserved residues and network of
water molecules within the binding site, they only bind with
moderate affinities. Alprazolam possesses the same triazole
ring and methyl group as the BET family inhibitors, but lacks
many of the other features of the designed inhibitors that con-
tribute to binding. Midazolam binds with an imidazole instead
of a triazole, potentially altering its binding with the conserved
asparagine, and also lacks the other molecular features of the
BET family inhibitors. On the other hand, the data show that
estazolam and triazolam do not bind to members of the BET
family. In the case of estazolam, this loss of affinity reinforces
the importance of the interaction between the methyl group of
the triazole ring and the base of the acetyl-lysine binding pocket
among the BET inhibitors, as this moiety is not present in estazo-
lam. The lack of affinity of triazolam for the acetyl-lysine binding
pocket shows that a large halogen at the ortho position of the
phenyl ring precludes binding. In terms of unintended effects,
the BZDs may interact with the BET bromodomains only in the
range of micromolar concentrations, indicating that gene tran-
scription-related side effects from BZDs prescribed as sedatives
do not appear likely to occur.
Alternatives Abound, but a Bright Future
A prime argument for using privileged scaffolds in drug develop-
ment is their ability to work on multiple targets. However, lead
compounds built on a core scaffold with potential activity for
multiple targets could also be difficult to optimize into a selective
drug with minimal off-target effects. As discussed previously, as
it pertains to JQ1 and the GABAA receptor, the diazepine-based
bromodomain inhibitors are tailored to target bromodomains via
added functional groups in an attempt to mitigate this risk. How-
ever, short of testing these compounds in human subjects, there
is no way to state this with certainty.iology 21, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 579
Chemistry & Biology
ReviewThe promise yet potential limitation of diazepine-based bro-
modomain inhibitors have inspired the development of other
classes of small molecule compounds with distinct scaffolds
as potent and selective bromodomain inhibitors. For instance,
a 1,3,4-benzotriazepine, BzT-7, shows submicromolar affinity
for the BET family, and displays the same binding mode as the
other BET family inhibitors (Filippakopoulos et al., 2012a).
Constellation Pharmaceuticals recently published binding, crys-
tallographic, and pharmacokinetic/pharmacodynamic (PK/PD)
data related to an isoxazole azepine compound, which takes
on a nearly identical binding mode as the diazepine inhibitors
described above (Figure 4F; Gehling et al., 2013). In the case
of this ligand, an isoxazole ring serves as the mimic of the acet-
ylated lysine instead of a triazole ring, and the group at position
C3 of the azepine ring is a primary carboxamide. Additional
compounds with cycloheptene and azepine scaffolds have
also been tested for their efficacy by Constellation, but their pre-
cise target binding and crystallographic data have not been
released (Albrecht et al., 2012).
Several groups have also utilized structure-guided fragment-
based drug design or virtual screening to discover and develop
BET family inhibitors that do not have a seven-membered ring
scaffold (Bamborough et al., 2012; Chung et al., 2012; Hewings
et al., 2011; Lucas et al., 2013; Picaud et al., 2013a; Seal et al.,
2012). Some of these compounds have a quinolone scaffold,
whereas others are still fragments based off of a phenyl group,
and are in the early stages of development. As is evident from
Constellation’s recent work, new ways to mimic the acetylated
lysine are also being explored, as researchers are attempting
to determine if inhibitors with an isoxazole ring as the acetyl-
lysine mimic are better candidates for future development than
the existing family of compounds that utilize the triazole ring
(Albrecht et al., 2012; Bamborough et al., 2012; Dawson et al.,
2011; Hewings et al., 2011;Mirguet et al., 2012; Seal et al., 2012).
Even as the efficacy and selectivity of alternative scaffolds are
actively being tested, the story of the triazolodiazepine family of
compounds remains incomplete due to their lack of selectivity
within the BET family. The current triazolodiazepines can be
further developed using structure-based rational drug design
into compounds selective for an individual protein among the
BET family members, or for one of the tandem bromodomains
of a single BET family member. For the latter, the potential for
success lies in the subtle variations between the tandem do-
mains of the BET proteins, such as Asp144 in BRD4-BrD1 and
its counterpart His433 in BRD4-BrD2 (orange highlights in Fig-
ures 4C–4F; Zhang et al., 2012). One quinazolone compound,
RVX-208, shows selectivity for BrD2s of the BET family mem-
bers, but lacks the potency of the diazepine compounds (Picaud
et al., 2013b). As currently constructed, the diazepine scaffold
has the space to accept additional functionality, allowing for
the potential development of a new compound that may favor
one BrD of a BET family member over the other, while maintain-
ing the potency of the current series of diazepine BET family in-
hibitors. With such inhibitors in hand, researchers could address
how the two tandem bromodomains of BET protein may function
differentially in control of gene transcription in chromatin.
The diazepine’s potential for inhibiting non-BET bromodo-
mains remains unclear. JQ1, MS417, and I-BET were all tested
against other bromodomains, including ones that have been580 Chemistry & Biology 21, May 22, 2014 ª2014 Elsevier Ltd All righreferred to as ‘‘druggable’’ (Vidler et al., 2012), yet each showed
selectivity only limited to the BET bromodomains (Filippakopou-
los et al., 2010; Nicodeme et al., 2010; Zhang et al., 2012). Both
the conserved structural fold among members of the bromodo-
main family and the diazepine’s ability to house numerous
functional groups could contribute to the construction of diaze-
pine-based compounds as inhibitors of other bromodomains.
For example, a fragment-based approach akin to the one used
in the search for alternative BET bromodomain inhibitors could
show that a diazepine binds deep within the binding pocket of
a non-BET bromodomain, making it a suitable scaffold to build
upon. The functional groups of JQ1, MS417, and I-BET may
have previously prevented such an interaction from being de-
tected, yet starting with a scaffold and building an inhibitor in a
rational manner to match an individual bromodomain may prove
to be successful.
Inhibitors of bromodomain-containing proteins are a part of
the extensive pipeline of epigenetic modulators that has the
potential to bring advanced, targeted treatments to patients in
the near future (Arrowsmith et al., 2012; Dawson et al., 2012;
DeWoskin and Million, 2013; Kelly et al., 2010). One of the
triazolodiazepines featured in this review, I-BET (GSK525762;
GlaxoSmithKline) has recently entered into a clinical trial for
NUT midline carcinoma. Other notable bromodomain inhibitors
are in the clinical development process for the treatment of
different diseases—TEN-010 (Tensha Therapeutics) for NUT
midline carcinoma, the quinazolone RVX-208 (Resverlogix) for
atherosclerosis and type 2 diabetes, OTX015 (Oncoethix) for he-
matological malignancies, and CPI-0610 (Constellation Pharma-
ceuticals) for progressive lymphoma (http://clinicaltrials.gov).
Aside from RVX-208, the bromodomain inhibitors being clinically
evaluated are diazepine-based compounds.
Recent studies detail additional potential breakthrough uses
of these compounds. JQ1 has been shown to cross the
hemato-testicular barrier and is being explored as an inhibitor
of BRDT for male contraception (Gaucher et al., 2012; Matzuk
et al., 2012). Data show that JQ1 can cross the blood-brain bar-
rier as well (Matzuk et al., 2012), leading researchers to test JQ1
against glioblastoma tumors, both in vitro and in an in vivomouse
model (Cheng et al., 2013). They found that JQ1 altered the levels
of multiple genes important to glioblastoma growth, slowed tu-
mor growth, and increased survival time in mice with tumors.
With the ability of the bromodomain-inhibiting diazepine com-
pounds to cross the blood-brain barrier and not have an effect
on neurological function, further testing is in order.
Conclusions
Privileged chemical scaffolds such as the diazepine play an
important role in drug design for new, targeted therapeutic treat-
ment for human disease. These scaffolds possess favorable
physiochemical and versatile structural qualities that make
them excellent templates for medicinal chemists to develop
lead inhibitors to modulate molecular functions of drug targets.
In the case of the diazepine scaffold, the unique geometry of
its seven-membered ring allows it to fit tightly in a binding site
while serving as a steady framework for the addition of functional
groups necessary to interact selectively with amino acid resi-
dues in a target protein, improving both affinity and selectivity.
This core structure fits the definition of a ‘‘privileged structure’’ts reserved
Chemistry & Biology
Reviewin drug design, because it forms the centerpiece of small mole-
cule chemical ligands that are constructed to target many
different receptors including GABAA, multiple enzymes, and
most recently, the epigenome-reading bromodomains. The
recent research into diazepine-based compounds as bromodo-
main inhibitors further highlights the great potential for this func-
tionally versatile scaffold to serve as a solid fundamental
chemical foundation upon which novel therapeutic agents are
being developed as new epigenetic therapies to treat a wide
range of human diseases including cancer and inflammation.
ACKNOWLEDGMENTS
We wish to thank Dr. Jamel Meslamani for discussion. This work was sup-
ported in part by the research grants from the National Institutes of Health
(to M.-M.Z.).
REFERENCES
Adachi, K., Hikawa, H., Hamada, M., Endoh, J.-i., Ishibuchi, S., Fujie, N.,
Tanaka, M., Sugahara, K., Oshita, K., and Murata, M. (July 2006). Thienotria-
zolodiazepine compound and a medicinal use thereof. Japan patent
WO2006JP310709.
Albrecht, B.K., Audia, J.E., Cote, A., Gehling, V.S., Harmange, J.-C., Hewitt,
M.C., LeBlanc, Y., Naveschuk, C.G., Taylor, A.M., and Vaswani, R.G. (June
2012). Bromodomain inhibitors and uses thereof. U.S. patent 20120157428 A1.
Amin, J., Brooks-Kayal, A., and Weiss, D.S. (1997). Two tyrosine residues on
the a subunit are crucial for benzodiazepine binding and allosteric modulation
of g-aminobutyric acidA receptors. Mol. Pharmacol. 51, 833–841.
Anderson, D.R., Meyers, M.J., Kurumbail, R.G., Caspers, N., Poda, G.I., Long,
S.A., Pierce, B.S., Mahoney, M.W., and Mourey, R.J. (2009). Benzothiophene
inhibitors of MK2. Part 1: structure-activity relationships, assessments of
selectivity and cellular potency. Bioorg. Med. Chem. Lett. 19, 4878–4881.
Argyropoulos, S.V., and Nutt, D.J. (1999). The use of benzodiazepines in
anxiety and other disorders. Eur. Neuropsychopharmacol. 9 (Suppl 6 ),
S407–S412.
Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K., and Schapira, M. (2012).
Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug
Discov. 11, 384–400.
Atack, J.R. (2005). The benzodiazepine binding site of GABA(A) receptors as a
target for the development of novel anxiolytics. Expert Opin. Investig. Drugs
14, 601–618.
Bamborough, P., Diallo, H., Goodacre, J.D., Gordon, L., Lewis, A., Seal, J.T.,
Wilson, D.M., Woodrow, M.D., and Chung, C.W. (2012). Fragment-based dis-
covery of bromodomain inhibitors part 2: optimization of phenylisoxazole sul-
fonamides. J. Med. Chem. 55, 587–596.
Belkina, A.C., and Denis, G.V. (2012). BET domain co-regulators in obesity,
inflammation and cancer. Nat. Rev. Cancer 12, 465–477.
Bermak, J., Johnstone, T., and Gee, K. (2007). Benzodiazepines. In Encyclo-
pedia of Stress, G. Fink, ed. (Waltham, MA: Academic Press), pp. 310–316.
Borea, P.A., and Bonora, A. (1983). Brain receptor binding and lipophilic char-
acter of benzodiazepines. Biochem. Pharmacol. 32, 603–607.
Buhr, A., Baur, R., Malherbe, P., and Sigel, E. (1996). Point mutations of the a 1
b 2 g 2 g-aminobutyric acid(A) receptor affecting modulation of the channel by
ligands of the benzodiazepine binding site. Mol. Pharmacol. 49, 1080–1084.
Buhr, A., Schaerer, M.T., Baur, R., and Sigel, E. (1997). Residues at positions
206 and 209 of the a1 subunit of g-aminobutyric AcidA receptors influence
affinities for benzodiazepine binding site ligands. Mol. Pharmacol. 52,
676–682.
Burger, A. (1991). Isosterism and bioisosterism in drug design. Prog. Drug Res.
37, 287–371.
Carlson, E.E. (2010). Natural products as chemical probes. ACS Chem. Biol. 5,
639–653.Chemistry & BCheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L.A., Thompson, R.C.,
Muller, S., Knapp, S., andWang, J. (2013). Inhibition of BET bromodomain tar-
gets genetically diverse glioblastoma. Clin. Cancer Res. 19, 1748–1759.
Chung, C.W. (2012). Small molecule bromodomain inhibitors: extending the
druggable genome. Prog. Med. Chem. 51, 1–55.
Chung, C.W., Coste, H., White, J.H., Mirguet, O., Wilde, J., Gosmini, R.L.,
Delves, C., Magny, S.M., Woodward, R., Hughes, S.A., et al. (2011). Discovery
and characterization of small molecule inhibitors of the BET family bromodo-
mains. J. Med. Chem. 54, 3827–3838.
Chung, C.W., Dean, A.W., Woolven, J.M., and Bamborough, P. (2012). Frag-
ment-based discovery of bromodomain inhibitors part 1: inhibitor binding
modes and implications for lead discovery. J. Med. Chem. 55, 576–586.
Costantino, L., and Barlocco, D. (2006). Privileged structures as leads in
medicinal chemistry. Curr. Med. Chem. 13, 65–85.
Crestani, F., Lo¨w, K., Keist, R., Mandelli, M.-J., Mo¨hler, H., and Rudolph, U.
(2001). Molecular targets for the myorelaxant action of diazepam. Mol.
Pharmacol. 59, 442–445.
Crestani, F., Keist, R., Fritschy, J.-M., Benke, D., Vogt, K., Prut, L., Blu¨thmann,
H., Mo¨hler, H., and Rudolph, U. (2002). Trace fear conditioning involves hippo-
campal a5 GABA(A) receptors. Proc. Natl. Acad. Sci. USA 99, 8980–8985.
Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M.,
Chan, W.-I., Robson, S.C., Chung, C.W., Hopf, C., Savitski, M.M., et al.
(2011). Inhibition of BET recruitment to chromatin as an effective treatment
for MLL-fusion leukaemia. Nature 478, 529–533.
Dawson, M.A., Kouzarides, T., and Huntly, B.J.P. (2012). Targeting epigenetic
readers in cancer. N. Engl. J. Med. 367, 647–657.
DeWoskin, V.A., and Million, R.P. (2013). The epigenetics pipeline. Nat. Rev.
Drug Discov. 12, 661–662.
Dhalluin, C., Carlson, J.E., Zeng, L., He, C., Aggarwal, A.K., and Zhou, M.-M.
(1999). Structure and ligand of a histone acetyltransferase bromodomain.
Nature 399, 491–496.
Dubnick, B., Lippa, A.S., Klepner, C.A., Coupet, J., Greenblatt, E.N., and Beer,
B. (1983). The separation of 3H-benzodiazepine binding sites in brain and of
benzodiazepine pharmacological properties. Pharmacol. Biochem. Behav.
18, 311–318.
Estes, J.W. (1995). The road to tranquility: the search for selective anti-anxiety
agents. Synapse 21, 10–20.
Evans, B.E., Bock, M.G., Rittle, K.E., DiPardo, R.M., Whitter, W.L., Veber, D.F.,
Anderson, P.S., and Freidinger, R.M. (1986). Design of potent, orally effective,
nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc. Natl.
Acad. Sci. USA 83, 4918–4922.
Evans, B.E., Rittle, K.E., Bock, M.G., DiPardo, R.M., Freidinger, R.M., Whitter,
W.L., Lundell, G.F., Veber, D.F., Anderson, P.S., Chang, R.S.L., et al. (1988).
Methods for drug discovery: development of potent, selective, orally effective
cholecystokinin antagonists. J. Med. Chem. 31, 2235–2246.
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O.,
Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., et al. (2010). Selective inhi-
bition of BET bromodomains. Nature 468, 1067–1073.
Filippakopoulos, P., Picaud, S., Fedorov, O., Keller, M., Wrobel, M., Morgen-
stern, O., Bracher, F., and Knapp, S. (2012a). Benzodiazepines and benzotria-
zepines as protein interaction inhibitors targeting bromodomains of the BET
family. Bioorg. Med. Chem. 20, 1878–1886.
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Bar-
syte-Lovejoy, D., Felletar, I., Volkmer, R., Mu¨ller, S., Pawson, T., et al.
(2012b). Histone recognition and large-scale structural analysis of the human
bromodomain family. Cell 149, 214–231.
Florence, B., and Faller, D.V. (2001). You bet-cha: a novel family of transcrip-
tional regulators. Front. Biosci. 6, D1008–D1018.
French, C.A., Miyoshi, I., Aster, J.C., Kubonishi, I., Kroll, T.G., Dal Cin, P., Var-
gas, S.O., Perez-Atayde, A.R., and Fletcher, J.A. (2001). BRD4 bromodomain
gene rearrangement in aggressive carcinoma with translocation t(15;19). Am.
J. Pathol. 159, 1987–1992.iology 21, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 581
Chemistry & Biology
ReviewFrench, C.A., Miyoshi, I., Kubonishi, I., Grier, H.E., Perez-Atayde, A.R., and
Fletcher, J.A. (2003). BRD4-NUT fusion oncogene: a novel mechanism in
aggressive carcinoma. Cancer Res. 63, 304–307.
French, C.A., Ramirez, C.L., Kolmakova, J., Hickman, T.T., Cameron, M.J.,
Thyne, M.E., Kutok, J.L., Toretsky, J.A., Tadavarthy, A.K., Kees, U.R., et al.
(2008). BRD-NUT oncoproteins: a family of closely related nuclear proteins
that block epithelial differentiation and maintain the growth of carcinoma cells.
Oncogene 27, 2237–2242.
Fryer, R.I., Leimgruber, W., and Trybulski, E.J. (1982). Quinazolines and 1,4-
benzodiazepines. 90. Structure-activity relationship between substituted
2-amino-N-(2-benzoyl-4-chlorophenyl)acetamides and 1,4-benzodiazepi-
nones. J. Med. Chem. 25, 1050–1055.
Furdas, S.D., Carlino, L., Sippl, W., and Jung, M. (2012). Inhibition of bromodo-
main-mediated protein-protein interactions as a novel therapeutic strategy.
Med Chem Commun 3, 123–134.
Gaucher, J., Boussouar, F., Montellier, E., Curtet, S., Buchou, T., Bertrand, S.,
Hery, P., Jounier, S., Depaux, A., Vitte, A.-L., et al. (2012). Bromodomain-
dependent stage-specific male genome programming by Brdt. EMBO J. 31,
3809–3820.
Gehling, V.S., Hewitt, M.C., Vaswani, R.G., Leblanc, Y., Cote, A., Nasveschuk,
C.G., Taylor, A.M., Harmange, J.-C., Audia, J.E., Pardo, E., et al. (2013). Dis-
covery, design, and optimization of isoxazole azepine BET inhibitors. ACS
Med. Chem. Lett. 4, 835–840.
Grasberger, B.L., Lu, T., Schubert, C., Parks, D.J., Carver, T.E., Koblish, H.K.,
Cummings, M.D., LaFrance, L.V., Milkiewicz, K.L., Calvo, R.R., et al. (2005).
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists
that activate p53 in cells. J. Med. Chem. 48, 909–912.
Griebel, G., and Holmes, A. (2013). 50 years of hurdles and hope in anxiolytic
drug discovery. Nat. Rev. Drug Discov. 12, 667–687.
Haskell-Luevano, C., Rosenquist, A., Souers, A., Khong, K.C., Ellman, J.A.,
and Cone, R.D. (1999). Compounds that activate the mouse melanocortin-1
receptor identified by screening a small molecule library based upon the
b-turn. J. Med. Chem. 42, 4380–4387.
Hewings, D.S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopou-
los, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., et al. (2011).
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
J. Med. Chem. 54, 6761–6770.
Horton, D.A., Bourne, G.T., and Smythe, M.L. (2003). The combinatorial syn-
thesis of bicyclic privileged structures or privileged substructures. Chem.
Rev. 103, 893–930.
Huang, Y., and Do¨mling, A. (2010). 1,4-Thienodiazepine-2,5-diones via MCR
(II): scaffold hopping by Gewald and Ugi-deprotection-cyclization strategy.
Chem. Biol. Drug Des. 76, 130–141.
Huang, Y., Wolf, S., Bista, M., Meireles, L., Camacho, C., Holak, T.A., and
Do¨mling, A. (2010). 1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, vir-
tual space and p53-Mdm2 activity. Chem. Biol. Drug Des. 76, 116–129.
Joseph, C.G., Wilson, K.R., Wood,M.S., Sorenson, N.B., Phan, D.V., Xiang, Z.,
Witek, R.M., and Haskell-Luevano, C. (2008). The 1,4-benzodiazepine-2,5-
dione small molecule template results in melanocortin receptor agonists with
nanomolar potencies. J. Med. Chem. 51, 1423–1431.
Kelly, T.K., De Carvalho, D.D., and Jones, P.A. (2010). Epigenetic modifica-
tions as therapeutic targets. Nat. Biotechnol. 28, 1069–1078.
Kucken, A.M., Wagner, D.A., Ward, P.R., Teisse´re, J.A., Boileau, A.J., and
Czajkowski, C. (2000). Identification of benzodiazepine binding site residues
in the g2 subunit of the g-aminobutyric acid(A) receptor. Mol. Pharmacol. 57,
932–939.
Leonard, K., Marugan, J.J., Raboisson, P., Calvo, R., Gushue, J.M., Koblish,
H.K., Lattanze, J., Zhao, S., Cummings, M.D., Player, M.R., et al. (2006). Novel
1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular
activity. Bioorg. Med. Chem. Lett. 16, 3463–3468.
Lipinski, C.A. (2004). Lead- and drug-like compounds: the rule-of-five revolu-
tion. Drug Discov. Today. Technol. 1, 337–341.
Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (2001). Experi-
mental and computational approaches to estimate solubility and permeability
in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26.582 Chemistry & Biology 21, May 22, 2014 ª2014 Elsevier Ltd All righLoew, G.H., Nienow, J.R., and Poulsen, M. (1984). Theoretical structure-activ-
ity studies of benzodiazepine analogues. Requirements for receptor affinity
and activity. Mol. Pharmacol. 26, 19–34.
Loudni, L., Roche, J., Potiron, V., Clarhaut, J., Bachmann, C., Gesson, J.-P.,
and Tranoy-Opalinski, I. (2007). Design, synthesis and biological evaluation
of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorg. Med.
Chem. Lett. 17, 4819–4823.
Lo¨w, K., Crestani, F., Keist, R., Benke, D., Bru¨nig, I., Benson, J.A., Fritschy,
J.-M., Ru¨licke, T., Bluethmann, H., Mo¨hler, H., and Rudolph, U. (2000). Molec-
ular and neuronal substrate for the selective attenuation of anxiety. Science
290, 131–134.
Lucas, X., Wohlwend, D., Hu¨gle, M., Schmidtkunz, K., Gerhardt, S., Schu¨le, R.,
Jung, M., Einsle, O., and Gu¨nther, S. (2013). 4-Acyl pyrroles: mimicking acet-
ylated lysines in histone code reading. Angew. Chem. Int. Ed. Engl. 52, 14055–
14059.
Matzuk, M.M., McKeown, M.R., Filippakopoulos, P., Li, Q., Ma, L., Agno, J.E.,
Lemieux, M.E., Picaud, S., Yu, R.N., Qi, J., et al. (2012). Small-molecule inhibi-
tion of BRDT for male contraception. Cell 150, 673–684.
McGowan, D., Nyanguile, O., Cummings, M.D., Vendeville, S., Vandyck, K.,
Van den Broeck, W., Boutton, C.W., De Bondt, H., Quirynen, L., Amssoms,
K., et al. (2009). 1,5-Benzodiazepine inhibitors of HCV NS5B polymerase.
Bioorg. Med. Chem. Lett. 19, 2492–2496.
McKernan, R.M., Rosahl, T.W., Reynolds, D.S., Sur, C., Wafford, K.A., Atack,
J.R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000). Sedative but not
anxiolytic properties of benzodiazepines are mediated by the GABA(A) recep-
tor a1 subtype. Nat. Neurosci. 3, 587–592.
Mertz, J.A., Conery, A.R., Bryant, B.M., Sandy, P., Balasubramanian, S., Mele,
D.A., Bergeron, L., and Sims, R.J., 3rd. (2011). Targeting MYC dependence in
cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA 108,
16669–16674.
Mirguet, O., Lamotte, Y., Donche, F., Toum, J., Gellibert, F., Bouillot, A., Gos-
mini, R., Nguyen, V.-L., Delanne´e, D., Seal, J., et al. (2012). From ApoA1 upre-
gulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg.
Med. Chem. Lett. 22, 2963–2967.
Mirguet, O., Gosmini, R., Toum, J., Cle´ment, C.A., Barnathan, M., Brusq,
J.-M., Mordaunt, J.E., Grimes, R.M., Crowe, M., Pineau, O., et al. (2013). Dis-
covery of epigenetic regulator I-BET762: lead optimization to afford a clinical
candidate inhibitor of the BET bromodomains. J. Med. Chem. 56, 7501–7515.
Miyoshi, S., Ooike, S., Iwata, K., Hikawa, H., and Sugahara, K. (November
2008). Antitumor agent. U.S. patent 20100286127 A1.
Mujtaba, S., Zeng, L., and Zhou, M.-M. (2007). Structure and acetyl-lysine
recognition of the bromodomain. Oncogene 26, 5521–5527.
Muller, S., Filippakopoulos, P., and Knapp, S. (2011). Bromodomains as ther-
apeutic targets. Expert Rev. Mol. Med. 13, e29.
Nash, J.R., and Nutt, D.J. (2007). Pharmacotherapy of anxiety. In Handbook of
Contemporary Neuropharmacology, D.R. Sibley, I. Hanin, M. Kuhar, and P.
Skolnick, eds. (Hoboken, NJ: John Wiley & Sons, Inc.), pp. 59–91.
Nicodeme, E., Jeffrey, K.L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.W.,
Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010). Suppression of
inflammation by a synthetic histone mimic. Nature 468, 1119–1123.
Nyanguile, O., Pauwels, F., Van den Broeck, W., Boutton, C.W., Quirynen, L.,
Ivens, T., van der Helm, L., Vandercruyssen, G., Mostmans, W., Delouvroy, F.,
et al. (2008). 1,5-benzodiazepines, a novel class of hepatitis C virus polymer-
ase nonnucleoside inhibitors. Antimicrob. Agents Chemother. 52, 4420–4431.
Olkkola, K.T., and Ahonen, J. (2008). Midazolam and other benzodiazepines.
Handbook Exp. Pharmacol. 182, 335–360.
Owen, D.J., Ornaghi, P., Yang, J.-C., Lowe, N., Evans, P.R., Ballario, P., Neu-
haus, D., Filetici, P., and Travers, A.A. (2000). The structural basis for the
recognition of acetylated histone H4 by the bromodomain of histone acetyl-
transferase gcn5p. EMBO J. 19, 6141–6149.
Patchett, A.A., and Nargund, R.P. (2000). Privileged Structures - An Update.
Annu. Rep. Med. Chem. 35, 289–298.
Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P.V.,
Philpott, M., Fedorov, O., Brennan, P., Bunnage, M.E., Owen, D.R., et al.ts reserved
Chemistry & Biology
Review(2013a). PFI-1, a highly selective protein interaction inhibitor, targeting BET
bromodomains. Cancer Res. 73, 3336–3346.
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-
Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013b). RVX-208, an
inhibitor of BET transcriptional regulators with selectivity for the second bro-
modomain. Proc. Natl. Acad. Sci. 110, 19754–19759.
Prinjha, R.K., Witherington, J., and Lee, K. (2012). Place your BETs: the thera-
peutic potential of bromodomains. Trends Pharmacol. Sci. 33, 146–153.
Pritchett, D.B., and Seeburg, P.H. (1991). g-Aminobutyric acid type A receptor
point mutation increases the affinity of compounds for the benzodiazepine
site. Proc. Natl. Acad. Sci. USA 88, 1421–1425.
Reid, T.S., and Beese, L.S. (2004). Crystal structures of the anticancer clinical
candidates R115777 (Tipifarnib) and BMS-214662 complexedwith protein far-
nesyltransferase suggest a mechanism of FTI selectivity. Biochemistry 43,
6877–6884.
Reynoird, N., Schwartz, B.E., Delvecchio, M., Sadoul, K., Meyers, D., Mukher-
jee, C., Caron, C., Kimura, H., Rousseaux, S., Cole, P.A., et al. (2010).
Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyper-
acetylated chromatin domains. EMBO J. 29, 2943–2952.
Richter, L., de Graaf, C., Sieghart, W., Varagic, Z., Mo¨rzinger, M., de Esch, I.J.,
Ecker, G.F., and Ernst, M. (2012). Diazepam-bound GABAA receptor models
identify new benzodiazepine binding-site ligands. Nat. Chem. Biol. 8, 455–464.
Rosenstro¨m, U., Sko¨ld, C., Lindeberg, G., Botros, M., Nyberg, F., Karle´n, A.,
and Hallberg, A. (2006). Design, synthesis, and incorporation of a b-turn
mimetic in angiotensin II forming novel pseudopeptides with affinity for AT1
and AT2 receptors. J. Med. Chem. 49, 6133–6137.
Rudolph, U., and Knoflach, F. (2011). Beyond classical benzodiazepines: novel
therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 10,
685–697.
Rudolph, U., Crestani, F., Benke, D., Bru¨nig, I., Benson, J.A., Fritschy, J.-M.,
Martin, J.R., Bluethmann, H., and Mo¨hler, H. (1999). Benzodiazepine actions
mediated by specific g-aminobutyric acid(A) receptor subtypes. Nature 401,
796–800.
Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nico-
deme, E., Krysa, G., Kirilovsky, J., Beinke, S., et al. (2012). Identification of a
novel series of BET family bromodomain inhibitors: binding mode and profile
of I-BET151 (GSK1210151A). Bioorg. Med. Chem. Lett. 22, 2968–2972.
Skolnick, P. (2012). Anxioselective anxiolytics: on a quest for the Holy Grail.
Trends Pharmacol. Sci. 33, 611–620.
Stahl, S.M. (2002). Don’t ask, don’t tell, but benzodiazepines are still the lead-
ing treatments for anxiety disorder. J. Clin. Psychiatry 63, 756–757.
Sternbach, L.H. (1979). The benzodiazepine story. J. Med. Chem. 22, 1–7.Chemistry & Bvan Rijnsoever, C., Ta¨uber, M., Choulli, M.K., Keist, R., Rudolph, U., Mohler,
H., Fritschy, J.-M., and Crestani, F. (2004). Requirement of a5-GABAA recep-
tors for the development of tolerance to the sedative action of diazepam in
mice. J. Neurosci. 24, 6785–6790.
Vandyck, K., Cummings, M.D., Nyanguile, O., Boutton, C.W., Vendeville, S.,
McGowan, D., Devogelaere, B., Amssoms, K., Last, S., Rombauts, K., et al.
(2009). Structure-based design of a benzodiazepine scaffold yields a potent
allosteric inhibitor of hepatitis C NS5B RNA polymerase. J. Med. Chem. 52,
4099–4102.
Verster, J.C., and Volkerts, E.R. (2004). Clinical pharmacology, clinical effi-
cacy, and behavioral toxicity of alprazolam: a review of the literature. CNS
Drug Rev. 10, 45–76.
Vidler, L.R., Brown, N., Knapp, S., and Hoelder, S. (2012). Druggability analysis
and structural classification of bromodomain acetyl-lysine binding sites.
J. Med. Chem. 55, 7346–7359.
Villar, H.O., Davies, M.F., Loew, G.H., and Maguire, P.A. (1991). Molecular
models for recognition and activation at the benzodiazepine receptor: a re-
view. Life Sci. 48, 593–602.
VonVoigtlander, P.F., and Straw, R.N. (1985). Alprazolam: review of pharma-
cological, pharmacokinetic, and clinical data. Drug Dev. Res. 6, 1–12.
Wang, Q., Han, Y., and Xue, H. (1999). Ligands of the GABAA receptor benzo-
diazepine binding site. CNS Drug Rev. 5, 125–144.
Welsch, M.E., Snyder, S.A., and Stockwell, B.R. (2010). Privileged scaffolds for
library design and drug discovery. Curr. Opin. Chem. Biol. 14, 347–361.
Wieland, H.A., and Lu¨ddens, H. (1994). Four amino acid exchanges convert a
diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diaz-
epam-preferring GABAA receptor. J. Med. Chem. 37, 4576–4580.
Wieland, H.A., Lu¨ddens, H., and Seeburg, P.H. (1992). A single histidine in
GABAA receptors is essential for benzodiazepine agonist binding. J. Biol.
Chem. 267, 1426–1429.
Wu, S.-Y., and Chiang, C.-M. (2007). The double bromodomain-containing
chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 282,
13141–13145.
Zhang, G., Liu, R., Zhong, Y., Plotnikov, A.N., Zhang, W., Zeng, L., Rusinova,
E., Gerona-Nevarro, G., Moshkina, N., Joshua, J., et al. (2012). Down-regula-
tion of NF-kB transcriptional activity in HIV-associated kidney disease by
BRD4 inhibition. J. Biol. Chem. 287, 28840–28851.
Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A.,
Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011). RNAi screen iden-
tifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478,
524–528.iology 21, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 583
